YN321140 Levalbuterol tartrate 661464-94-4

Levalbuterol HCl is a relatively selective beta2-adrenergic receptor agonist used for the treatment of asthma.

YN320601 D3-βArr 662164-09-2

D3-βArr is a positive allosteric modulator forthyrotropin receptor (TSHR), which initiates translocation of β-Arr 1 by direct TSHR activation and potentiates TSH-mediated preosteoblast differentiation in vitro.

YN321794 Motixafortide 664334-36-5

Motixafortide (BL-8040, BKT140, TF 14016, 4-fluorobenzoyl, 4F-benzoyl-TN14003, T140) is an antagonist of CXCR4 with IC50 of ～1 nM. BL-8040 induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MC...

YN321024 Vercirnon 698394-73-9

Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist ofCCR9. Vercirnon inhibits CCR9-mediated Ca2+mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4nM, respectiv...

YN320817 GSK189254A 720690-73-3

GSK189254A (GSK189254) is a novel, potent and selective histamineH3receptor antagonist with pKi values. of 9.59-9.90 and 8.51-9.17 for human and rat H3, respectively.

YN321063 Relugolix 737789-87-6

Relugolix is a selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) with an IC50 of 0.12 nM.

YN320671 Batefenterol 743461-65-6

Batefenterol (GSK961081, TD-5959) is both a muscarinic receptor antagonist and a β2-adrenoceptor agonist with Ki of 1.4 nM, 1.3 nM and 3.7 nM for hM2, hM3 muscarinic receptors and hβ2-adrenoceptor, respectively.

YN320929 Taprenepag 752187-80-7

Taprenepag (CP-544326) is a potent and selectiveprostagl and in EP(2)agonist with IC50s of 10 and 15nM for human and rat EP2, respectively. Taprenepag shows selectivity for EP2 over other EP receptors (IC50s>3200nM f...

YN320845 Indacaterol maleate 753498-25-8

Indacaterol is an ultra-long-acting β-adrenoceptor agonist with pKi of 7.36 for β1-adrenoceptor and pKi of 5.48 for β2-adrenoceptor.

YN440253 NVP-TAE 226 761437-28-9

TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met.

YN360698 KM11060 774549-97-2

KM11060 is a corrector of the F508 deletion (F508del)-cystic fibrosis transmembrane conductance regulator (CFTR) trafficking defect. KM11060 can be used for the research of F508del-CFTR processing defect and development of ...

YN320390 SB-334867 free base 792173-99-0

SB-334867 is a selective orexin-1 (OX1) receptor antagonist.

YN321049 AZD1981 802904-66-1

AZD1981 is a potent, selective CRTh2 (DP2) receptor antagonist with IC50 of 4 nM, showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1. Phase 2.

YN320909 Retosiban 820957-38-8

Retosiban (GSK221149A) is a potent and selective oxytocin antagonist with a Ki of 0.65nM.

YN320860 Elagolix sodium 832720-36-2

Elagolix Soidum is a potent, selective, orally active, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) with Kd value of 54 pM. Concentration at 10 μM shows no significant activity on ion channels, en...

YN320913 (R)-Elagolix 834153-87-6

Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).

YN320790 CAY10471 Racemate 844639-57-2

CAY10471 Racemate (TM30089 Racemate) is a potent and highly selectiveprostagl and in D2 receptor CRTH2antagonist, with a Ki of 0.6nM for hCRTH2, selective over human thromboxane A2 receptor TP (Ki, >10000nM) or PG...

YN320347 CJ-42794 847728-01-2

CJ-42794 is a selective prostagl and in E receptor subtype 4 (EP4) antagonist, inhibits [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5, a binding affinity that was at least 200-fold more selective for the hum...

YN320472 H4 Receptor antagonist 1 848217-00-5

H4 Receptor antagonist 1 is a potent and selectivehistamine H4 receptorinverse agonist, with an IC50 of 19nM.

YN320596 ML604086 850330-18-6

ML604086 is a selectiveCCR8inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca2+concentrations.